Through this investment, Helios develops a strategic partnership that aims at synergistic effects of the development of cancer immunity cell therapy centered on Gaia BioMedicine’s know-how on NK cells, and Helios’ own specialized stem cell technology. In addition, Helios will purchase shares of Gaia Biochemical Corporation. Natural killer (NK) cells are a naturally occurring defense mechanism in the human body. The leukocyte attacks cancer cells and virus-infected cells, and in the classification of white blood cells is classified as a lymphocyts. The effectiveness of treatment with NK cells is expected to extend life expectancy, alleviate symptoms, improve quality of life, and cure.
Gaia BioMedicine news release, February 14, 2018
Helios invests in Gaia BioMedicine for NK